AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16342925 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated imatinib treatment (65% favorable survival times)
Number of subjects: 0
Study 16342925 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated imatinib treatment (50% favorable survival times)
Number of subjects: 0
Study 12083753 — intervention group
Group type: EXPERIMENTAL
Intervention: Counselors‐CARE (C‐CAST)
Number of subjects: 341
Study 12083753 — intervention group
Group type: EXPERIMENTAL
Intervention: Coping and Support Training (CAST)
Number of subjects: 341
Study 12083753 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 341
Study 9649993 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimal-flow anaesthesia (0.5 L min-1 fresh gas inflow)
Number of subjects: 13
Study 9649993 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-flow anaesthesia (3 L min-1 fresh gas flow)
Number of subjects: 13
Study 9649993 — intervention group
Group type: EXPERIMENTAL
Intervention: Desorption of adsorbed desflurane
Number of subjects: 13
Study 7655967 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed technique
Number of subjects: 95
Study 2570043 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiologist provided with ejection fraction results
Number of subjects: 60
Study 2570043 — intervention group
Group type: COMPARATOR
Intervention: Ejection fraction results withheld from cardiologist
Number of subjects: 60
Study 1028636 — intervention group
Group type: EXPERIMENTAL
Intervention: Digoxin
Number of subjects: 4
Study 1028636 — intervention group
Group type: COMPARATOR
Intervention: Beta-methyl-digoxin
Number of subjects: 4
Study 31100199 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise
Number of subjects: 120
Study 31100199 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of aerobic and resistance exercise
Number of subjects: 120
Study 31100199 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 27597129 — intervention group
Group type: EXPERIMENTAL
Intervention: eCHECKUP TO GO for High School
Number of subjects: 0
Study 27597129 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 26357907 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based healthy relationships video groups (HR-VG) delivered at home
Number of subjects: 21
Study 26357907 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based healthy relationships video groups (HR-VG) delivered at community-based organizations (CBOs)
Number of subjects: 21
Study 23123375 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg extended release oxybutynin daily
Number of subjects: 50
Study 23123375 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 21515120 — intervention group
Group type: EXPERIMENTAL
Intervention: Small food-item size (candies cut in two)
Number of subjects: 33
Study 21515120 — intervention group
Group type: COMPARATOR
Intervention: Large food-item size (whole candies)
Number of subjects: 33
Study 19030986 — intervention group
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Number of subjects: 0
Study 19030986 — intervention group
Group type: COMPARATOR
Intervention: Exemestane
Number of subjects: 0
Study 16247504 — intervention group
Group type: EXPERIMENTAL
Intervention: Ghrelin (3.6 nmol/kg)
Number of subjects: 16
Study 16247504 — intervention group
Group type: COMPARATOR
Intervention: Saline (control)
Number of subjects: 16
Study 14685866 — intervention group
Group type: EXPERIMENTAL
Intervention: Adults
Number of subjects: 29
Study 14685866 — intervention group
Group type: COMPARATOR
Intervention: Propelling surface size
Number of subjects: 29
Study 10868824 — intervention group
Group type: EXPERIMENTAL
Intervention: HOE 901
Number of subjects: 333
Study 10868824 — intervention group
Group type: COMPARATOR
Intervention: NPH insulin
Number of subjects: 333
Study 9195242 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous autologous transfusion system (CATS)
Number of subjects: 10
Study 1363204 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbon dioxide laser
Number of subjects: 50
Study 1363204 — intervention group
Group type: COMPARATOR
Intervention: Trichloroacetic acid (TCA)
Number of subjects: 50
Study 4029473 — intervention group
Group type: EXPERIMENTAL
Intervention: Electronic fetal monitoring (EFM)
Number of subjects: 655
Study 4029473 — intervention group
Group type: COMPARATOR
Intervention: Auscultation (AUS)
Number of subjects: 655
Study 2454373 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 50 mg
Number of subjects: 13
Study 2454373 — intervention group
Group type: EXPERIMENTAL
Intervention: Pindolol 10 mg
Number of subjects: 13
Study 2454373 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 13
Study 2454373 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 2454373 — intervention group
Group type: EXPERIMENTAL
Intervention: All medications
Number of subjects: 13
Study 31310186 — intervention group
Group type: EXPERIMENTAL
Intervention: Involvement by family in care and discharge planning (contacting family members, communicating about the patient's health, and discharge plan)
Number of subjects: 179
Study 31310186 — intervention group
Group type: EXPERIMENTAL
Intervention: Family phone calls and/or visits with patients, attendance at family therapy sessions, communication with inpatient staff about services available to families
Number of subjects: 179
Study 31310186 — intervention group
Group type: EXPERIMENTAL
Intervention: Inpatient staff contacting a family member
Number of subjects: 179
Study 31310186 — intervention group
Group type: EXPERIMENTAL
Intervention: Attendance at outpatient appointments
Number of subjects: 179
Study 28337872 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg ropivacaine (0.50%)
Number of subjects: 180
Study 28337872 — intervention group
Group type: EXPERIMENTAL
Intervention: 12 mg ropivacaine (0.50%)
Number of subjects: 180
Study 28337872 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 mg ropivacaine (0.50%)
Number of subjects: 180
Study 26159013 — intervention group
Group type: EXPERIMENTAL
Intervention: Peitu Shengjin Recipe (PSR), one dose per day
Number of subjects: 62
Study 26159013 — intervention group
Group type: COMPARATOR
Intervention: Seretide (50/500 µg), twice per day
Number of subjects: 62
Study 23200261 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato product (TP) consumption - one serving per day for 3 months
Number of subjects: 36
Study 23200261 — intervention group
Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 36
Study 23200261 — intervention group
Group type: EXPERIMENTAL
Intervention: Tomato product (TP) consumption
Number of subjects: 36
Study 21168923 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% levobupivacaine with 1:200,000 epinephrine
Number of subjects: 60
Study 21168923 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25% bupivacaine with 1:200,000 epinephrine
Number of subjects: 60
Study 21168923 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 60
Study 18048590 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 9
Study 18048590 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 9
Study 16501800 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative intra-aortic balloon (IAB)
Number of subjects: 239
Study 16501800 — intervention group
Group type: COMPARATOR
Intervention: Control group (surgery without circulatory assistance)
Number of subjects: 239
Study 12548303 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteral diet supplemented with arginine and dietary fibre (group I, n=18)
Number of subjects: 36
Study 12548303 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric, isonitrogenous enteral formula (group II, n=18)
Number of subjects: 36
Study 10894991 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐dopa + lisuride
Number of subjects: 82
Study 10894991 — intervention group
Group type: COMPARATOR
Intervention: L‐dopa alone
Number of subjects: 82
Study 8936782 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnipaque 300
Number of subjects: 110
Study 8936782 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnipaque 240
Number of subjects: 110
Study 8936782 — intervention group
Group type: EXPERIMENTAL
Intervention: Omnipaque 180
Number of subjects: 110
Study 8936782 — intervention group
Group type: COMPARATOR
Intervention: Diagnostic lumbar puncture
Number of subjects: 110
Study 1402720 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-stimulus intervals (RSI) of 500 ms
Number of subjects: 0
Study 1402720 — intervention group
Group type: EXPERIMENTAL
Intervention: Response-stimulus intervals (RSI) of 4,000 ms
Number of subjects: 0
Study 1402720 — intervention group
Group type: COMPARATOR
Intervention: Equal RSI and preceding RSI
Number of subjects: 0
Study 1402720 — intervention group
Group type: EXPERIMENTAL
Intervention: Blocked RSI and preceding RSI
Number of subjects: 0
Study 4059296 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g triletide
Number of subjects: 45
Study 4059296 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 g triletide
Number of subjects: 45
Study 4059296 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g triletide
Number of subjects: 45
Study 4059296 — intervention group
Group type: COMPARATOR
Intervention: Dose correlation
Number of subjects: 45
Study 4059296 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses
Number of subjects: 45
Study 30872064 — intervention group
Group type: EXPERIMENTAL
Intervention: BIAsp 30 TID
Number of subjects: 437
Study 30872064 — intervention group
Group type: COMPARATOR
Intervention: BIAsp 30 BID
Number of subjects: 437
Study 29945918 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 18 mg
Number of subjects: 159
Study 29945918 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 90 mg
Number of subjects: 159
Study 29945918 — intervention group
Group type: EXPERIMENTAL
Intervention: Risankizumab 180 mg
Number of subjects: 159
Study 29945918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 27792133 — intervention group
Group type: EXPERIMENTAL
Intervention: Walnut consumption
Number of subjects: 64
Study 27792133 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 25006678 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergocalciferol (50,000 IU weekly for one month followed by 50,000 IU monthly)
Number of subjects: 38
Study 25006678 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study 22643537 — intervention group
Group type: EXPERIMENTAL
Intervention: Imatinib mesylate (400 mg/day for 36 months)
Number of subjects: 397
Study 22643537 — intervention group
Group type: COMPARATOR
Intervention: Imatinib mesylate (400 mg/day for 12 months)
Number of subjects: 397
Study 20391952 — intervention group
Group type: EXPERIMENTAL
Intervention: Octatropine plus diazepam (Valpinax) 40 mg/2.5 mg twice daily for 6 weeks
Number of subjects: 186
Study 20391952 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 6 weeks
Number of subjects: 186
Study 18272290 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (Nicorette 2 mg gum)
Number of subjects: 0
Study 18272290 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15721731 — intervention group
Group type: EXPERIMENTAL
Intervention: 500‐mg paracetamol + 75‐mg caffeine
Number of subjects: 210
Study 15721731 — intervention group
Group type: EXPERIMENTAL
Intervention: 500‐mg paracetamol + 125‐mg caffeine
Number of subjects: 210
Study 15721731 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study 12099151 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level laser therapy (LLLT)
Number of subjects: 15
Study 12099151 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 15
Study 9861379 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroquine syrup (25 mg/kg)
Number of subjects: 117
Study 9861379 — intervention group
Group type: COMPARATOR
Intervention: Pyrimethamine/sulfadoxine
Number of subjects: 117
Study 7898741 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional antiepileptic drugs (monotherapy)
Number of subjects: 0
Study 7898741 — intervention group
Group type: EXPERIMENTAL
Intervention: Polypharmacy
Number of subjects: 0
Study 7898741 — intervention group
Group type: EXPERIMENTAL
Intervention: New antiepileptic agents
Number of subjects: 0
Study 2146130 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac (200 to 300 mg b.i.d. or 200 mg t.i.d.)
Number of subjects: 0
Study 2146130 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac (200 mg b.i.d.)
Number of subjects: 0
Study 2146130 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac (50 to 200 mg b.i.d.)
Number of subjects: 0
Study 2146130 — intervention group
Group type: COMPARATOR
Intervention: Naproxen (250 to 375 mg b.i.d.)
Number of subjects: 0
Study 2146130 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 374176 — intervention group
Group type: EXPERIMENTAL
Intervention: Motilin infusion (0.34 pmol/kg/min for 60 min, followed by 0.68 pmol/kg/min for 60 min)
Number of subjects: 5
Study 374176 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion (control)
Number of subjects: 5
Study 374176 — intervention group
Group type: EXPERIMENTAL
Intervention: Motilin infusion (high dose)
Number of subjects: 5
Study 374176 — intervention group
Group type: EXPERIMENTAL
Intervention: Motilin infusion (low dose)
Number of subjects: 5
Study 374176 — intervention group
Group type: EXPERIMENTAL
Intervention: Motilin infusion
Number of subjects: 5
Study 29214826 — intervention group
Group type: EXPERIMENTAL
Intervention: Sedentary intervention (eliminate all exercise and minimize steps to ≤5000 steps/day for 1 week)
Number of subjects: 33
Study 29214826 — intervention group
Group type: COMPARATOR
Intervention: Normal physical activity (control group continued normal PA levels for 1 week)
Number of subjects: 33
Study 26631103 — intervention group
Group type: EXPERIMENTAL
Intervention: 150-mg Artemisia annua extract (ART) twice daily (BD)
Number of subjects: 42
Study 26631103 — intervention group
Group type: COMPARATOR
Intervention: Placebo BD
Number of subjects: 42
Study 26631103 — intervention group
Group type: EXPERIMENTAL
Intervention: 300-mg Artemisia annua extract (ART) twice daily (BD)
Number of subjects: 42
Study 23611363 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual daily pain treatment with acetaminophen, extended release morphine, buprenorphine transdermal patch, and/or pregabaline for 8 weeks
Number of subjects: 352
Study 23611363 — intervention group
Group type: COMPARATOR
Intervention: Usual treatment and care
Number of subjects: 352
Study 22258482 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanercept treatment
Number of subjects: 0
Study 19931345 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandibular-implant overdentures
Number of subjects: 173
Study 19931345 — intervention group
Group type: COMPARATOR
Intervention: Conventional dentures
Number of subjects: 173
Study 17373915 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin (1200 mg/day)
Number of subjects: 64
Study 17373915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 16371674 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed amphetamine salts extended release (Adderall XR)
Number of subjects: 203
Study 16371674 — intervention group
Group type: COMPARATOR
Intervention: Atomoxetine (Strattera)
Number of subjects: 203
Study 12214785 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural prevention session during hospitalization
Number of subjects: 258
Study 12214785 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural programme with 5-8 weekly home-visits
Number of subjects: 258
Study 12214785 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 258
Study 9748032 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTA)
Number of subjects: 42
Study 9748032 — intervention group
Group type: EXPERIMENTAL
Intervention: Trihexyphenidyl
Number of subjects: 42
Study 7920454 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone (300 mg/day for 5 days) in normal subjects
Number of subjects: 13
Study 7920454 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone (300 mg/day for 5 days) in patients with renal disease
Number of subjects: 13
Study 2838979 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (75-100 mg/d)
Number of subjects: 18
Study 30096440 — intervention group
Group type: EXPERIMENTAL
Intervention: Volunteer-provided palliative care services for people with cancer
Number of subjects: 157
Study 30096440 — intervention group
Group type: COMPARATOR
Intervention: Volunteer-provided palliative care services for people without cancer
Number of subjects: 157
Study 30096440 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life physical domain
Number of subjects: 157
Study 30096440 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life environmental domain
Number of subjects: 157
Study 26069034 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower nicotine metabolite ratio (NMR <0.31)
Number of subjects: 1155
Study 26069034 — intervention group
Group type: COMPARATOR
Intervention: Nicotine patch
Number of subjects: 1155
Study 26069034 — intervention group
Group type: COMPARATOR
Intervention: Varenicline
Number of subjects: 1155
Study 25261324 — intervention group
Group type: EXPERIMENTAL
Intervention: Pedometer-based programme
Number of subjects: 102
Study 25261324 — intervention group
Group type: COMPARATOR
Intervention: Standard programme of physical activity encouragement
Number of subjects: 102
Study 23359236 — intervention group
Group type: EXPERIMENTAL
Intervention: Polyethylene plastic drape
Number of subjects: 60
Study 23359236 — intervention group
Group type: COMPARATOR
Intervention: Conventional cotton drape
Number of subjects: 60
Study 20800244 — intervention group
Group type: EXPERIMENTAL
Intervention: Histidine-tryptophan-ketoglutarate (HTK)
Number of subjects: 80
Study 20800244 — intervention group
Group type: COMPARATOR
Intervention: Cold blood cardioplegia
Number of subjects: 80
Study 18485612 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Skills with Behavioral Couples Therapy (PSBCT)
Number of subjects: 30
Study 18485612 — intervention group
Group type: COMPARATOR
Intervention: Behavioral Couples Therapy (BCT)
Number of subjects: 30
Study 18485612 — intervention group
Group type: COMPARATOR
Intervention: Individual-Based Treatment (IBT)
Number of subjects: 30
Study 16825135 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% albumin
Number of subjects: 21
Study 16825135 — intervention group
Group type: COMPARATOR
Intervention: isotonic saline
Number of subjects: 21
Study 16825135 — intervention group
Group type: COMPARATOR
Intervention: hydroxyethyl starch (HES)
Number of subjects: 21
Study 12931755 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva incubation test
Number of subjects: 8
Study 12931755 — intervention group
Group type: COMPARATOR
Intervention: Hydrogen sulphide (H2S) measurement devices
Number of subjects: 8
Study 12931755 — intervention group
Group type: COMPARATOR
Intervention: Organoleptic ratings
Number of subjects: 8
Study 10828704 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium
Number of subjects: 33
Study 10828704 — intervention group
Group type: COMPARATOR
Intervention: Methyldopa
Number of subjects: 33
Study 9124658 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA grade <= 2 and cardiac risk index group I (score 0-5 points)
Number of subjects: 16227
Study 9124658 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA grade = 4 and cardiac risk index group >= 3 (score > 13 points)
Number of subjects: 16227
Study 9124658 — intervention group
Group type: EXPERIMENTAL
Intervention: ASA grade and cardiac risk index combined
Number of subjects: 16227
Study 7518763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil 10 mg/kg twice daily for 10 days
Number of subjects: 74
Study 7518763 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 10 mg/kg twice daily for 10 days
Number of subjects: 74
Study 7518763 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefetamet pivoxil
Number of subjects: 74
Study 7518763 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor
Number of subjects: 74
Study 2972165 — intervention group
Group type: EXPERIMENTAL
Intervention: remoxipride (75‐375 mg daily)
Number of subjects: 61
Study 2972165 — intervention group
Group type: COMPARATOR
Intervention: thioridazine (150‐750 mg daily)
Number of subjects: 61
Study 31585495 — intervention group
Group type: EXPERIMENTAL
Intervention: Transanal irrigation (TAI)
Number of subjects: 23
Study 31585495 — intervention group
Group type: COMPARATOR
Intervention: Percutaneous tibial nerve stimulation (PTNS)
Number of subjects: 23
Study 30391300 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarker feedback intervention (n=30)
Number of subjects: 60
Study 30391300 — intervention group
Group type: COMPARATOR
Intervention: Contact control usual care condition (n=30)
Number of subjects: 60
Study 28288601 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal behavioral intervention (MBI) treatment including telephone counseling, nicotine replacement therapy, mobile app support, multimedia text messages about TSE and smoking cessation.
Number of subjects: 100
Study 28288601 — intervention group
Group type: COMPARATOR
Intervention: Attention control intervention including nutrition-focused telephone counseling, mobile app, multimedia text messages about improving nutrition, and referral to state smoking cessation quitline.
Number of subjects: 100
Study 24837362 — intervention group
Group type: EXPERIMENTAL
Intervention: CE 0.625 mg/BZA 20 mg
Number of subjects: 4
Study 24837362 — intervention group
Group type: EXPERIMENTAL
Intervention: CE 0.45 mg/BZA 20 mg
Number of subjects: 4
Study 24837362 — intervention group
Group type: COMPARATOR
Intervention: CE/BZA (both doses)
Number of subjects: 4
Study 24837362 — intervention group
Group type: EXPERIMENTAL
Intervention: CE/BZA (higher dose)
Number of subjects: 4
Study 22852560 — intervention group
Group type: EXPERIMENTAL
Intervention: Genetic counseling regarding risk for DM
Number of subjects: 600
Study 22852560 — intervention group
Group type: COMPARATOR
Intervention: Conventional risk counseling for DM with eye disease counseling
Number of subjects: 600
Study 20164800 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BoNT‐A) injection
Number of subjects: 19
Study 20164800 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 20164800 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (BoNT‐A and placebo)
Number of subjects: 19